Online ISSN: 1949-2553
www.oncotarget.com
About Oncotarget
Our mission is to make scientific results rapidly and widely available. We seek to maximize the impact of research via insightful review, to enable exceptional discoveries to be shared quickly, to eliminate the border between specialties, to link different fields of biomedical science, and to foster application of basic and clinical science to fight disease.

LEARN MORE ABOUT ONCOTARGET

Assessment of Serum Tumor Markers CEA, CA-125, and CA19-9 as Adjuncts in Non-small Cell Lung Cancer Management

News

June 19, 2024
PRESS RELEASE: On June 13, 2024, a new research paper was published in Oncotarget, entitled, “Assessment of serum tumor markers CEA, CA-125, and CA19-9 as adjuncts in non-small cell lung cancer management.” continue reading »

When Does a Melanoma Metastasize? Implications for Management

News

June 18, 2024
PRESS RELEASE: On June 13, 2024, a new research perspective was published in Oncotarget, entitled, “When does a melanoma metastasize? Implications for management.” continue reading »

Dr. Blagosklonny’s Strategy: From Osimertinib to Preemptive Combinations

Oncotarget

June 6, 2024
This article dissects Dr. Mikhail V. Blagosklonny’s paradigm-shifting perspective on preemptive combinations for treating EGFR-mutant non-small cell lung cancer. continue reading »

Synergistic Cytotoxicity of HDAC and PARP Inhibitors and Decitabine in Pancreatic Cancer Cells: Implications for Novel Therapy

News

June 5, 2024
PRESS RELEASE: On June 3, 2024, a new research paper was published in Oncotarget, entitled, “Synergistic cytotoxicity of histone deacetylase and poly-ADP ribose polymerase inhibitors and decitabine in pancreatic cancer cells: Implications for novel therapy.” continue reading »

Behind the Study: Anticancer Potential of CLK Kinase Inhibitors 1C8 and GPS167

Oncotarget

May 30, 2024